Product Name: Enzalutamide (MDV3100)Request Enzalutamide (MDV3100)
Synonym:MDV-3100; MDV 3100; MDV 3100; Enzalutamide, brand name: Xtandi. ,
Enzalutamide (MDV3100) Chemical Structure
5 stars, based on 1836 reviewsIUPAC/Chemical name:
Price of Enzalutamide (MDV3100) We offer a substantial discount on larger orders,
please inquire via email@example.com
or Fax: 1-201-884-1288 (USA Fax#)
Biological Activity Enzalutamide, also known as MDV3100, is an orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, selective androgen receptor modulator MDV3100 inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. AR over-expression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance. MDV3100 was discovered by Charles Sawyers who is now at Memorial Sloan–Kettering Cancer Center and Michael Jung at UCLA. MDV3100 is an experimental androgen receptor antagonist drug developed by the pharmaceutical company Medivation for the treatment of castration-resistant prostate cancer currently in Phase 3 clinical trials. Results so far have been encouraging; Medivation has reported up to an 89% decrease in prostate specific antigen serum levels after a month of taking the medicine. Early preclinical studies also suggest that MDV3100 inhibits breast cancer cell growth.
Purchase(buy) Enzalutamide (MDV3100) at Active Biochem
and the United State(U.S.), Germany, Japan, France,United Kingdom(UK),Switzerland, Australia distributors.